Abstract:Integrins reside on cell surfaces in an equilibrium between inactive and active conformations. When inactive, the transmembrane (TM) domains of integrin α and β subunits interact, but the domains separate when integrins assume their active conformation. Although this conformational change has not been shown for αvβ3, we hypothesized that a peptide designed to bind to the αv TM domain might activate αvβ3 in platelets by disrupting the TM domain heterodimer of the inactive molecule. To design such a peptide, we used CHAMP (Computed Helical Anti-Membrane Protein) methodology. In the CHAMP method, the αv TM helix was scanned for motifs likely to mediate αvβ3 TM domain interactions. Next, the backbone conformation for an αv-binding peptide was selected based on known structural preferences for the motifs identified in the αv helix. Finally, the sequence for the peptide was designed computationally using a side-chain repacking algorithm. The CHAMP peptide, anti-αv, and its TM helix target, αv-TM, were synthesized by solid phase synthesis. We also synthesized anti-αvmut in which the putative anti-αv-TM binding motif, GXXXG, was mutated to LXXXL. Lys2 dipeptides and short polyethylene glycol sequences were appended to the C- and N-termini of the peptides, respectively, to facilitate their solubility and insertion into membranes. CD spectroscopy revealed that both anti-αv and αv-TM were helical in micelles and phospholipid vesicles. Measurement of Trp fluorescence intensity revealed that anti-αv rapidly inserted into unilamellar POPC/POPG vesicles. Analytical ultracentrifuge and fluorescence resonance energy transfer experiments demonstrated that anti-αv bound to the αv-TM, but not to a homologous αIIb-TM domain peptide. In addition, there was negligible interaction between αv-TM and anti-αvmut. Anti-αv also formed heteromeric complexes with the αv TM domain in bacterial membranes but not with the TM domains of αIIb, α2, β1, or β3. αvβ3 mediates the adhesion of agonist-stimulated platelets to the matrix protein osteopontin (OPN). We found that anti-αV at μM concentrations induced platelet adhesion to OPN. Adhesion was prevented by the divalent cation chelator EDTA, consistent with an integrin-mediated process, but was only minimally affected by pre-incubating the platelets with PGE1, implying that anti-αv-induced adhesion by interacting directly with the αv TM domain. Force spectroscopy using laser tweezers confirmed the specificity of the interaction of anti-αv with platelets: anti-αv induced specific rupture forces between platelets and OPN-coated beads, but not between platelets and fibrinogen-coated beads. Moreover, only non-specific rupture forces were detected between OPN-coated beads and platelets incubated with anti-αvmut. These results demonstrate the successful application of computational methods to design a soluble peptide that specifically recognizes the TM domain of αv in platelets membranes, even when a 400-fold excess of the homologous integrin subunit αIIb is present. Further, because the peptide binds to the site on the αv TM domain that interacts with the β3 TM helix and activates αvβ3, these results strongly support the hypothesis that separation of the αv and β3 TM domains regulates the function of this integrin.

Apolipoprotein Α-IV is a Novel Ligand of Platelet Αiibβ3 Integrin and an Endogenous Thrombosis Inhibitor: Measurement of Single-Molecular Interactions by Biomembrane Force Probe

Apolipoprotein A-IV binds αIIbβ3 integrin and inhibits thrombosis

Structural analyses of apolipoprotein A-IV polymorphisms Q360H and T347S elucidate the inhibitory effect against thrombosis

Structure, signal transduction, activation, and inhibition of integrin αIIbβ3

Regulation of the Function of Αvβ3 in Platelets by a Designed Peptide Targeting the Αv Transmembrane Domain.

A Novel Anti-Platelet Peptide (Z4A5) Potential for Glycoprotein IIb/IIIa Inhibits Platelet Aggregation

Platelet Integrin Alpha Iib Beta 3: Signal Transduction, Regulation, And Its Therapeutic Targeting

Platelet integrin αIIbβ3: signal transduction, regulation, and its therapeutic targeting

Mechanisms of Αiibβ3 Biogenesis in the Megakaryocyte: A Proteomics Approach

Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus

Structure, signal transduction, activation, and inhibition of integrin IIb3

Apolipoprotein A-IV Regulates Chylomicron Metabolism-Mechanism and Function.

Structure, signal transduction, activation, and inhibition of integrin alpha IIb beta 3

Apolipoprotein B100/Low-Density Lipoprotein Regulates Proteolysis and Functions of von Willebrand Factor under Arterial Shear

Platelet ADP Receptor P2Y12 Stabilizes Atherosclerosis Plaques by Regulating Alpha Granule Release and Inflammatory Cell Recruitment

An Unexpected Role for Αiibβ3 in Immune Complex Disorders

Distinct platelet interactions with soluble and immobilized von Willebrand factor modulate platelet adhesion and aggregation with differential impact on hemostasis and thrombosis

The integrin PSI domain has an endogenous thiol isomerase function and is a novel target for antiplatelet therapy

A Model of Lipid-Free Apolipoprotein A-I Revealed by Iterative Molecular Dynamics Simulation

Clathrin-mediated Integrin Αiibβ3 Trafficking Controls Platelet Spreading.

Integrin Αiib-Mediated PI3K/Akt Activation in Platelets